In a poster discussion session at the American Society of Clinical Oncology meeting in Chicago, IL, Daniel George, MD, of Duke University Medical Center discussed updated results from a phase II study of orteronel, a selective oral 17,20-lyase inhibitor dosed without prednisone in patients with nonmetastatic castrate-resistant prostate cancer and rising prostate-specific antigen (PSA). The primary objective of the study was to determine the percentage of patients achieving a PSA reduction to 0.2 ng/ml or less (undetectable levels) after three months. The study included 39 patients and showed the following results.
Moskowitz, C. S., Chou, J. F., Wolden, S. L., Bernstein, J. L., Malhotra, J., Friedman, D. N., … Oeffinger, K. C. (2012, June). New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study. Abstract presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.
Leonard, R., et al. (2011, September). The effects of rheology and type of thickening agent on objective swallowing parameters. Poster session presented at the 1st Congress of the European Society for Swallowing Disorders, Leiden, The Netherlands.